Clinical management of gastrointestinal stromal tumors: Before and after STI-571

Kindblom, 1998, Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal, Am J Pathol, 152, 1259 Sarlomo-Rikala, 1998, CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34, Mod Pathol, 11, 728 Miettinen, 1995, Gastrointestinal stromal tumors—Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas, Am J Surg Pathol, 19, 207, 10.1097/00000478-199502000-00009 Hirota, 1998, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, 577, 10.1126/science.279.5350.577 Lux, 2000, KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors, Am J Pathol, 156, 791, 10.1016/S0002-9440(10)64946-2 Blanke Berman, 2001, Gastrointestinal stromal tumor workshop, Hum Pathol, 32, 578, 10.1053/hupa.2001.25484 DeMatteo, 2000, Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival, Ann Surg, 231, 51, 10.1097/00000658-200001000-00008 Shiu, 1982, Myosarcomas of the stomach: natural history, prognostic factors and management, Cancer, 49, 177, 10.1002/1097-0142(19820101)49:1<177::AID-CNCR2820490136>3.0.CO;2-K Ng, 1992, Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging, Ann Surg, 215, 68, 10.1097/00000658-199201000-00010 Miettinen, 1999, Gastrointestinal stromal tumors: recent advances in understanding of their biology, Hum Pathol, 30, 1213, 10.1016/S0046-8177(99)90040-0 Pisters, 1996, Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma, J Clin Oncol, 14, 859, 10.1200/JCO.1996.14.3.859 Yang, 1998, Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity, J Clin Oncol, 16, 197, 10.1200/JCO.1998.16.1.197 Pollock, 2001, Adjuvant radiotherapy for gastrointestinal stromal tumor of the rectum, Dig Dis Sci, 46, 268, 10.1023/A:1005581000712 Shioyama, 2001, Long-term control for a retroperitoneal metastasis of malignant gastrointestinal stromal tumor after chemoradiotherapy and immunotherapy, Acta Oncol, 40, 102, 10.1080/028418601750071154 Crosby, 2001, Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database, Ann Surg Oncol, 8, 50, 10.1007/s10434-001-0050-4 Ng, 1992, Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas, Cancer, 69, 1334, 10.1002/1097-0142(19920315)69:6<1334::AID-CNCR2820690606>3.0.CO;2-S Mudan, 1999, Salvage surgery in recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection, Cancer, 88, 66, 10.1002/(SICI)1097-0142(20000101)88:1<66::AID-CNCR10>3.0.CO;2-0 Van Glabbeke, 1999, J Clin Oncol, 17, 150, 10.1200/JCO.1999.17.1.150 Edmondson, 1999, Contrast of response to D-MAP + sargramostim between patients with advance malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas, Proc ASCO, 18, 541a Goss, 2000, Clinical and pathological characteristics of gastrointenstinal stromal tumors, Proc ASCO, 19, 2203 Plaat, 2000, Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins, J Clin Oncol, 18, 3211, 10.1200/JCO.2000.18.18.3211 Bedi, 1994, Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia, Blood, 83, 2038, 10.1182/blood.V83.8.2038.2038 Ning, 2001, Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells, Leuk Lymphoma, 41, 513, 10.3109/10428190109060342 Berthet, 1999, Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment, Eur J Cancer, 35, 413, 10.1016/S0959-8049(98)00375-X Eilber, 1999, Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas, Ann Surg Oncol, 6, 645, 10.1007/s10434-999-0645-8 Eilber, 2000, Recurrent gastrointestinal stromal sarcomas, Surg Oncol, 9, 71, 10.1016/S0960-7404(00)00026-8 Rajan, 2001, Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol chemoembolization, J Vasc Interv Radiol, 12, 187, 10.1016/S1051-0443(07)61824-7 Mavligit, 1995, Gastrointestinal leiomyosarcoma metastatic to the liver: Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine, Cancer, 75, 2083, 10.1002/1097-0142(19950415)75:8<2083::AID-CNCR2820750809>3.0.CO;2-H DeMatteo, 2001, Results of hepatic resection for sarcoma metastatic to liver, Ann Surg, 234, 540, 10.1097/00000658-200110000-00013 Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat Med, 2, 561, 10.1038/nm0596-561 Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med, 344, 1031, 10.1056/NEJM200104053441401 Druker, 2001, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome, N Engl J Med, 344, 1038, 10.1056/NEJM200104053441402 Buchdunger, 1996, Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative, Cancer Res, 56, 100 Heinrich, 2000, Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor, Blood, 96, 925, 10.1182/blood.V96.3.925 Buchdunger, 2000, Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors, J Pharmacol Exp Ther, 295, 139 Tuveson, 2001, STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications, Oncogene, 20, 5054, 10.1038/sj.onc.1204704 Heinrich, 2000, STI571 inhibits the kinase activity of wild type and juxtamembrane c-kit mutants but not the exon 17 D816V mutation associated with mastocytosis, Blood, 96, A4459 Joensuu, 2001, Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor, N Engl J Med, 344, 1052, 10.1056/NEJM200104053441404 Van den Abbeele, 2001, F18-FDG-PET provides early evidence of biological response to STI 571 in patients with malignant gastrointestinal stromal tumors (GIST), ASCO Proc, 20, 144 Van Oosterom, 2001, STI 571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study, ASCO Proc, 20, 2 Van Oosterom, 2001, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: A phase I study, Lancet, 358, 1421, 10.1016/S0140-6736(01)06535-7 American College of Surgeons Oncology Group. www.acosog.org. Nishida, 1998, Familial gastrointestinal stromal tumours with germline mutation of the KIT gene, Nat Genet, 19, 323, 10.1038/1209 Lasota, 1999, Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas, Am J Pathol, 154, 53, 10.1016/S0002-9440(10)65250-9 Taniguchi, 1999, Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors, Cancer Res, 59, 4297 Lasota, 2001, Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases, Am J Pathol, 157, 1091, 10.1016/S0002-9440(10)64623-8 Rubin, 2001, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors, Cancer Res, 61, 8118 Ernst, 1998, KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors, Lab Invest, 78, 1633 El Rifai, 2000, DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance, Cancer Res, 60, 3899 Gorre, 2001, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science, 293, 876, 10.1126/science.1062538 le Coutre, 2000, Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification, Blood, 95, 1758, 10.1182/blood.V95.5.1758.005a41_1758_1766 Mahon, 2000, Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance, Blood, 96, 1070, 10.1182/blood.V96.3.1070 Weisberg, 2000, Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines, Blood, 95, 3498, 10.1182/blood.V95.11.3498 Sjoblom, 2001, Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis, Cancer Res, 61, 5778 Zalupski, 1991, Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study, J Natl Cancer Inst, 83, 926, 10.1093/jnci/83.13.926 Antman, 1993, An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas, J Clin Oncol, 11, 1276, 10.1200/JCO.1993.11.7.1276 Elias, 1989, Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy, J Clin Oncol, 7, 1208, 10.1200/JCO.1989.7.9.1208 Blair, 1994, Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas, Am J Clin Oncol, 17, 480, 10.1097/00000421-199412000-00005 Balcerzak, 1995, A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study, Cancer, 76, 2248, 10.1002/1097-0142(19951201)76:11<2248::AID-CNCR2820761111>3.0.CO;2-Y Patel, 2001, Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation, J Clin Oncol, 19, 3483, 10.1200/JCO.2001.19.15.3483 Le Cesne, 2000, J Clin Oncol, 18, 2676, 10.1200/JCO.2000.18.14.2676 Verweij, 2000, Randomized phase II study of docetaxel versus doxorubicin in f, J Clin Oncol, 18, 2081, 10.1200/JCO.2000.18.10.2081 Nielsen, 2000, Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group, Eur J Cancer, 36, 61, 10.1016/S0959-8049(99)00240-3 Frustaci, 1993, Epirubicin and ifosfamide in advanced soft tissue sarcomas, Ann Oncol, 4, 669, 10.1093/oxfordjournals.annonc.a058622